Sacramento, California 95817


Purpose:

The purpose of this trial is to compare two different rates of fluid administration during diabetic ketoacidosis (DKA) treatment in children to determine which fluid administration rate is more beneficial for brain metabolism and for preventing or decreasing brain swelling during DKA.


Study summary:

Cerebral edema (swelling of the brain) is the most frequent serious complication of diabetic ketoacidosis (DKA) in children. The cause of cerebral edema during DKA is not well understood. Recent studies suggest that it may result from lack of adequate blood flow to the brain during DKA, before treatment starts. Brain injury, resulting in edema, may occur before treatment because of lack of adequate blood flow to the brain and additional injury may occur when adequate blood flow is re-established during treatment (called reperfusion injury). Because additional injury may occur during treatment, it is important to understand whether the rate of administration of intravenous fluids, and, therefore, the speed of reperfusion of the brain, is related to the degree of brain swelling and injury. Most current treatment protocols indicate that intravenous fluids should be administered slowly, but it may be possible that brain injury and swelling might be lessened if adequate blood flow is established more quickly. In this study, researchers will use magnetic resonance (MR) imaging to compare two different rates of fluid administration during DKA treatment in children. The investigators will use MR imaging to measure brain swelling and metabolism at three time points—twice during treatment and once after recovery from DKA—and will compare these measurements to determine which fluid administration rate has more beneficial effects on brain metabolism and brain swelling. The study's researchers hypothesize that more rapid re-establishment of blood flow to the brain (via more rapid administration of intravenous fluids) will result in less brain swelling and injury than slower rehydration with delayed re-establishment of adequate brain blood flow will.


Criteria:

Inclusion Criteria: - age 8-18 years - diagnosis of diabetic ketoacidosis - able to cooperate with MR scanning Exclusion Criteria: - pre-existing cerebral injury or brain structural abnormality - dental hardware or other metal devices which would interfere with MR imaging


NCT ID:

NCT00629707


Primary Contact:

Principal Investigator
Nicole Glaser, MD
University of California, Davis

Nicole Glaser, MD
Phone: 916-734-0406
Email: nsglaser@ucdavis.edu


Backup Contact:

N/A


Location Contact:

Sacramento, California 95817
United States

Nicole Glaser, MD
Phone: 916-734-0406
Email: nsglaser@ucdavis.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 23, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.